Dr. Jason Kelly is Co-Founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food and energy industries. The company recently raised over $430M to expand their automated genetic engineering foundries. They have a $100M joint venture with Bayer to develop microbes for self-fertilizing crops, a $160M partnership with Roche to develop antibiotics and with Motif for making animal-free protein ingredients. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering.